Austria : Novel chalcone derivative for cancer treatment

Novel chalcone derivative for cancer treatment From these tests, one representative emerged (APG38), which inhibits proliferation of CLL cells in vitro at very low concentrations and simultaneously displays less effect on healthy donor cell growth.

 

Innovations offered:

 

 

Currently:

 

 

Preferred Cooperation:

□ Commercial Agreement with technical assistance

R Technical Cooperation Agreement

□ Financial Investment Agreement

□ Joint Venture

R Licensing Agreement

□ Manufacturing Agreement

□ Research Collaboration Agreement

□ Services Agreement

 

Type of Partner sought:

Copyright © 2018 CHINA INTERNATIONAL TECHNOLOGY TRANSFER CENTER